Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy Subjects

Chiesi

Status and phase: Completed; Phase 1

Conditions: COPD; Chronic Obstructive Pulmonary Disease (COPD)

Treatments: Drug: CHF6001

Study type: Interventional

Funder types: Industry

Identifiers

NCT04756960

CLI-06001AA1-02

2020-004201-31 (EudraCT Number)

Details and patient eligibility

About

The objective of the study is to evaluate the bioavailability of CHF6001 after inhaled administration, to characterize the mass balance and route of elimination of CHF6001 along with its relevant metabolites, in healthy male subjects.

Full description

This clinical trial is a single centre Phase I study, with a single dose, non-randomized, open-label, uncontrolled design. A total of 8 healthy male subjects were included in the study.

The aim was to assess the absolute bioavailability, the mass balance, and routes of elimination of CHF6001 (Tanimilast) in healthy male subjects, using [14^C]-radiolabelled drug substance, administered as an intravenous (iv) infusion concomitantly with an inhaled (inh) non-radiolabelled dose of CHF6001.

Standard safety assessments were conducted during the study, including safety blood and urine laboratory tests, vital signs, physical examinations, ECGs, and assessment of any adverse events (AE). Blood, urine, and feces samples were collected for pharmacokinetic (PK) analyses.

Enrollment: 8 patients

Sex: Male

Ages: 30 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Subject's written informed consent obtained prior to any study-related procedure;
2. Able to understand the study procedures, the risks involved and ability to be trained to use correctly the inhalers and to generate sufficient Peak Inspiratory Flow (PIF), using the In-Check device and Placebo inhaler;
3. Male subjects aged 30 to 55 years inclusive;
4. Body mass index (BMI) within the range of 18 to 35 kg/m^2 inclusive;
5. Non- or ex-smoker who smoked < 5 pack years and who stopped smoking > 1 year prior to screening;
6. Good physical and mental status;
7. Vital signs at screening within limits;
8. 12-lead digitised Electrocardiogram (12-lead ECG) in triplicate considered as normal;
9. Lung function measurements within normal limits at screening;
10. Regular bowel movements at screening;
11. Males with non-pregnant Women of Childbearing Potential (WOCBP) partners: they and/or their partner of childbearing potential must be willing to use a highly effective birth control method in addition to the male condom from the signature of the informed consent and until 90 days after the follow-up visit. Males with pregnant WOCBP partner: they must be willing to use male contraception (condom) from the signature of the informed consent and until 90 days after the follow-up visit.

Exclusion criteria

1. Participation in another clinical trial with an investigational drug in the 3 months or 5 half-lives of that investigational drug (whichever is longer) preceding the administration of the study drug;
2. Clinically relevant and uncontrolled respiratory, cardiac, hepatic (including Gilbert syndrome), gastrointestinal, renal, endocrine, metabolic, neurologic, or psychiatric disorder;
3. Clinically relevant abnormal laboratory values;
4. Subjects with history of breathing problems;
5. Positive to Human Immunodeficiency Virus 1/Human Immunodeficiency Virus 2 (HIV1/HIV2) serology at screening;
6. Positive results from the Hepatitis serology which indicates acute or chronic Hepatitis B or Hepatitis C at screening;
7. Blood donation or blood loss (equal or more than 450 mL) less than 2 months prior screening or prior to treatment;
8. Positive urine test for cotinine;
9. Documented history of alcohol abuse within 12 months prior to screening or a positive alcohol breath test;
10. Documented history of drug abuse within 12 months prior to screening or a positive urine drug screen;
11. Intake of non-permitted concomitant medications in the predefined period;
12. Presence of any current infection, or previous infection that resolved less than 7 days prior to screening or before treatment;
13. Known intolerance and/or hypersensitivity to any of the excipients contained in the formulation used in the trial;
14. Unsuitable veins for repeated venipuncture;
15. Heavy caffeine drinker;
16. Abnormal haemoglobin level at screening;
17. Subjects using e-cigarettes within 6 months prior to screening;
18. Subjects been involved in a study involving a 14^C-labeled drug within the 12 months prior to enrollment;
19. Subjects with exposure to significant diagnostic or therapeutic radiation or current employment in a job requiring radiation exposure monitoring within 12 months prior to Day-1;
20. Documented coronavirus disease 2019 (COVID-19) diagnosis within the last 8 weeks or which has not resolved within 14 days prior to screening and before treatment.

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

8 participants in 1 patient group

CHF6001

Experimental group

Description:

single dose of CHF6001 dry-powder inhaler (DPI) co-administered with an intravenous microdose of \[14\^C\]-labelled CHF6001

Treatment:

Drug: CHF6001